Search Results for "Apokyn"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Apokyn. Results 1 to 4 of 4 total matches.
See also: apomorphine

Sublingual Apomorphine (Kynmobi) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020  (Issue 1609)
of apomorphine (Apokyn) has been available for years for the same indication in patients with advanced PD.1 ...
The FDA has approved a sublingual fi lm formulation of the nonergot dopamine agonist apomorphine (Kynmobi – Sunovion) for acute, intermittent treatment of "off" episodes in patients with Parkinson's disease (PD). A subcutaneous formulation of apomorphine (Apokyn) has been available for years for the same indication in patients with advanced PD.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):165-6 |  Show IntroductionHide Introduction

Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021  (Issue 1615)
(Nourianz).1-3 Subcutaneous (Apokyn) or sublingual (Kynmobi) apomorphine4 or an orally inhaled dry-powder ...
The FDA has approved opicapone (Ongentys – Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an adjunct to carbidopa/levodopa in adults with Parkinson’s disease (PD) who experience "off" episodes. It is the third COMT inhibitor to be approved for this indication; tolcapone (Tasmar, and generics) and entacapone (Comtan, and generics) were approved earlier. Opicapone has been available in Europe since 2016.
Med Lett Drugs Ther. 2021 Jan 11;63(1615):3-5 |  Show IntroductionHide Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
, 8 mg/24 hr patches14 1 patch (4-8 mg) q24 hrs15 712.50 Subcutaneous Apomorphine – Apokyn (Supernus ...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 |  Show IntroductionHide Introduction

Comparison Table: Drugs for Parkinson's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
Apokyn (Supernus) 30 mg/3 mL cartridges iSupplied with a reusable pen injector (Apokyn Pen) and 6 ...
View the Comparison Table: Drugs for Parkinson's Disease
Med Lett Drugs Ther. 2021 Feb 22;63(1618):e1-9 |  Show IntroductionHide Introduction